FDA Gains No Impartiality Benefit From Conflict-Of-Interest Policy, Advocates Say
Executive Summary
Friends of Cancer Research cites an FDA-sponsored study to argue that agency adherence to an advisory committee conflict-of-interest policy that is stricter than required by law does not increase the impartiality of panel members’ recommendations.
You may also be interested in...
FDA Advisory Committee Waivers Reflect Recruitment Challenges
Recent waivers allowing the participation of outside experts at drug-related advisory committee meetings reflect FDA's difficulties in finding qualified individuals to provide advice on specialized topics.
Conflict-Of-Interest Policy Relaxation For FDA Cmtes. Could Be Easy PDUFA Add-on
FDA Commissioner Margaret Hamburg’s willingness to explore changes in conflict-of-interest policies for advisory committee members, coupled with a push for reforms by industry and lawmakers, suggests a relaxation of current screening requirements could become an easy add-on to the Prescription Drug User Fee Act reauthorizing legislation in 2012.
Conflict-Of-Interest Policy Relaxation For FDA Cmtes. Could Be Easy PDUFA Add-on
FDA Commissioner Margaret Hamburg’s willingness to explore changes in conflict-of-interest policies for advisory committee members, coupled with a push for reforms by industry and lawmakers, suggests a relaxation of current screening requirements could become an easy add-on to the Prescription Drug User Fee Act reauthorizing legislation in 2012.